Debiopharm

Debiopharm

we develop for patients

Location
Roles tracked
0
In pipeline
0
Tracking since

At a glance

You're tracking 0 roles at Debiopharm. Track a role to start building momentum here.

Company intel

From the job board · LinkedIn data via posting sync
Industry
Pharmaceutical Manufacturing
Company size
467 people
Headquarters
Lausanne +1 more
Founded
1979
Type
Self-Owned
Total funding
$4.7M

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

drug development digital health oncology antimicrobials Healthcare Biopharmaceutical drug delivery Science and innovation Radioligand Therapy Antibody Drug Conjugates DNA Damage Response Inhibition and ADC Linker

Open roles at Debiopharm